Efficacy of "Kardiovitin" in integrated treatment in arterial hypertension patients

Elena Katamanova; Elena Beygel; Oxana Ushakova; Irina Kudaeva; Nataliya Pavlenko

doi:10.1051/e3sconf/202021017001

All issues

Volume 210 (2020)

E3S Web Conf., 210 (2020) 17001

References

Open Access

Issue		E3S Web Conf. Volume 210, 2020 Innovative Technologies in Science and Education (ITSE-2020)


Article Number		17001
Number of page(s)		9
Section		Social Determinants and Health Behaviors
DOI		https://doi.org/10.1051/e3sconf/202021017001
Published online		04 December 2020

J, Jordan, C, Kurschat, H, Reuter, Arterial Hypertension, Dtsch Arztebl Int. 20, 115(33-34), 557-568 (2018) doi: 10.3238/arztebl.2018.0557 [Google Scholar]
L. A. Strizhakov, S. A. Babanov, Arterial hypertension at the workplace: risk factors and the population value, Arkh. 20, 90(9), 138-143 (2018) doi: 10.26442/terarkh2018909138-143 [Google Scholar]
K. Dumor, M. Shoemaker-Moyle, R. Nistala, Arterial Stiffness in Hypertension: an Update, Curr Hypertens Rep, 4, 20(8),72 (2018) doi: 10.1007/s11906-018-0867-x [CrossRef] [Google Scholar]
R. Mrowka, Arterial hypertension, Acta Physiol (Oxf), 219(4), 697-699 (2017) doi: 10.1111/apha.12855. [CrossRef] [Google Scholar]
2018 ESC/ESH Guidelines for the management of arterial hypertension. Russian Journal of Cardiology, 23(12), 143-228 (2018) doi: 10.1093/eurheartj/ehy339 [Google Scholar]
I. Chazova, Arterial hypertension in the light of current recommendations, Ter Arkh, 20, 90(9), 4-7 (2018) doi: 10.26442/terarkh20189094-7 [Google Scholar]
U. O. Wenzel, M. Bode, J. Köhl, H. Am J. Ehmke, A pathogenic role of complement in arterial hypertension and hypertensive end organ damage, Physiol Heart Circ Physiol. 1, 312(3), 349-354 (2017) doi: 10.1152/ajpheart.00759.2016. Epub [CrossRef] [Google Scholar]
I. Chazova, Yu. Zhernakova, Diagnosis and treatment of Arterial hypertension [Guidelines]. Sistemnyye gipertenzii, 16(1), 6-31 (2019) doi: 10.26442/2075082X.2019.1.190179 [Google Scholar]
R. Patel, B. Mistry Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem, 15, 889-904 (2018) doi: 10.1016/j.ejmech.2018.06.053. [CrossRef] [Google Scholar]
K. Manigandan, R. Jayaraj, N. Elangovan, Taxifolin ameliorates 1, 2-dimethylhydrazine induced cellproliferation and redox avulsions in mice colon carcinogenesi. Biomedicine [amp] Preventive Nutrition, 4, 499-509 (2014) http://dx.doi.org/10.1016/j.bionut.2014.08.00 [CrossRef] [Google Scholar]
Y. Zhang, J. Yu, X. D. Dong, H. Y. Ji, Molecules, Research on Characteristics, Antioxidant and Antitumor Activities of Dihydroquercetin and Its Complexes, 22, 23(1), 20 (2017) doi: 10.3390/molecules23010020 [Google Scholar]
K. Asmi, T. Lakshmi, S. Balusamy, Therapeutic aspects of taxifolin – An update. Journal of Advanced Pharmacy Education [amp] Research. Published by SPER Publications, 7, 187-189 (2017) https://japer.in/storage/models/article/ [Google Scholar]
M. B. Plotnikov, O. I. Aliev, A. V. Sidekhmenova, Dihydroquercetin Improves Microvascularization and Microcirculation in the Brain Cortex of SHR Rats during the Development of Arterial Hypertension, Bull Exp Biol Med, 163(1), 57-60 (2017) doi: 10.1007/s10517-017-3737-7 [CrossRef] [PubMed] [Google Scholar]
Z. Shu, Y. Yang, L. Yang, Cardioprotective effects of dihydroquercetin against ischemia reperfusion injury by inhibiting oxidative stress and endoplasmic reticulum stress-induced apoptosis via the PI3K/Akt pathway, Food Funct, 22, 10(1), 203-215 (2019) doi: 10.1039/c8fo01256c [CrossRef] [Google Scholar]
D. Konukoglu, H. Uzun, Endothelial Dysfunction and Hypertension, Adv Exp Med Biol, 956, 511-540 (2017) doi: 10.1007/5584_2016_90 [CrossRef] [PubMed] [Google Scholar]
A. Daiber, S. Steven, A. Weber, Targeting vascular (endothelial) dysfunction, Br J Pharmacol, 174(12), 1591-1619 (2017) doi: 10.1111/bph.13517. Epub 2016 Jul 4. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.

[1] J, Jordan, C, Kurschat, H, Reuter, Arterial Hypertension, Dtsch Arztebl Int. 20, 115(33-34), 557-568 (2018) doi: 10.3238/arztebl.2018.0557 [Google Scholar]

[2] L. A. Strizhakov, S. A. Babanov, Arterial hypertension at the workplace: risk factors and the population value, Arkh. 20, 90(9), 138-143 (2018) doi: 10.26442/terarkh2018909138-143 [Google Scholar]

[3] K. Dumor, M. Shoemaker-Moyle, R. Nistala, Arterial Stiffness in Hypertension: an Update, Curr Hypertens Rep, 4, 20(8),72 (2018) doi: 10.1007/s11906-018-0867-x [CrossRef] [Google Scholar]

[4] R. Mrowka, Arterial hypertension, Acta Physiol (Oxf), 219(4), 697-699 (2017) doi: 10.1111/apha.12855. [CrossRef] [Google Scholar]

[5] 2018 ESC/ESH Guidelines for the management of arterial hypertension. Russian Journal of Cardiology, 23(12), 143-228 (2018) doi: 10.1093/eurheartj/ehy339 [Google Scholar]

[6] I. Chazova, Arterial hypertension in the light of current recommendations, Ter Arkh, 20, 90(9), 4-7 (2018) doi: 10.26442/terarkh20189094-7 [Google Scholar]

[7] U. O. Wenzel, M. Bode, J. Köhl, H. Am J. Ehmke, A pathogenic role of complement in arterial hypertension and hypertensive end organ damage, Physiol Heart Circ Physiol. 1, 312(3), 349-354 (2017) doi: 10.1152/ajpheart.00759.2016. Epub [CrossRef] [Google Scholar]

[8] I. Chazova, Yu. Zhernakova, Diagnosis and treatment of Arterial hypertension [Guidelines]. Sistemnyye gipertenzii, 16(1), 6-31 (2019) doi: 10.26442/2075082X.2019.1.190179 [Google Scholar]

[9] R. Patel, B. Mistry Therapeutic potential of quercetin as a cardiovascular agent. Eur J Med Chem, 15, 889-904 (2018) doi: 10.1016/j.ejmech.2018.06.053. [CrossRef] [Google Scholar]

[10] K. Manigandan, R. Jayaraj, N. Elangovan, Taxifolin ameliorates 1, 2-dimethylhydrazine induced cellproliferation and redox avulsions in mice colon carcinogenesi. Biomedicine [amp] Preventive Nutrition, 4, 499-509 (2014) http://dx.doi.org/10.1016/j.bionut.2014.08.00 [CrossRef] [Google Scholar]

[11] Y. Zhang, J. Yu, X. D. Dong, H. Y. Ji, Molecules, Research on Characteristics, Antioxidant and Antitumor Activities of Dihydroquercetin and Its Complexes, 22, 23(1), 20 (2017) doi: 10.3390/molecules23010020 [Google Scholar]

[12] K. Asmi, T. Lakshmi, S. Balusamy, Therapeutic aspects of taxifolin – An update. Journal of Advanced Pharmacy Education [amp] Research. Published by SPER Publications, 7, 187-189 (2017) https://japer.in/storage/models/article/ [Google Scholar]

[13] M. B. Plotnikov, O. I. Aliev, A. V. Sidekhmenova, Dihydroquercetin Improves Microvascularization and Microcirculation in the Brain Cortex of SHR Rats during the Development of Arterial Hypertension, Bull Exp Biol Med, 163(1), 57-60 (2017) doi: 10.1007/s10517-017-3737-7 [CrossRef] [PubMed] [Google Scholar]

[14] Z. Shu, Y. Yang, L. Yang, Cardioprotective effects of dihydroquercetin against ischemia reperfusion injury by inhibiting oxidative stress and endoplasmic reticulum stress-induced apoptosis via the PI3K/Akt pathway, Food Funct, 22, 10(1), 203-215 (2019) doi: 10.1039/c8fo01256c [CrossRef] [Google Scholar]

[15] D. Konukoglu, H. Uzun, Endothelial Dysfunction and Hypertension, Adv Exp Med Biol, 956, 511-540 (2017) doi: 10.1007/5584_2016_90 [CrossRef] [PubMed] [Google Scholar]

[16] A. Daiber, S. Steven, A. Weber, Targeting vascular (endothelial) dysfunction, Br J Pharmacol, 174(12), 1591-1619 (2017) doi: 10.1111/bph.13517. Epub 2016 Jul 4. [CrossRef] [PubMed] [Google Scholar]